Related by context. All words. (Click for frequent words.) 78 refractory multiple myeloma 76 refractory chronic lymphocytic 76 refractory AML 76 relapsed multiple myeloma 74 leukemia AML 74 dasatinib Sprycel ® 74 recurrent NSCLC 73 refractory CLL 73 cell lymphoma CTCL 73 systemic anaplastic large 73 erlotinib Tarceva ® 73 alvespimycin 72 metastatic renal cell carcinoma 72 refractory metastatic colorectal cancer 72 oral ridaforolimus 72 refractory NSCLC 72 lintuzumab SGN 72 refractory cutaneous T 72 metastatic hormone refractory 72 Tarceva TM 72 refractory Hodgkin lymphoma 72 HER2 positive metastatic breast 72 tanespimycin 72 cutaneous T cell 72 cutaneous T 72 mRCC 72 relapsed MM 72 relapsing multiple sclerosis 72 metastatic CRC 72 leukemia CLL 71 VELCADE melphalan 71 recurrent glioblastoma multiforme 71 docetaxel Taxotere R 71 phase IIb clinical 71 Pemetrexed 71 Phase #b/#a clinical 71 metastatic GIST 71 Cutaneous T 71 Amrubicin 71 treatment naive genotype 71 heavily pretreated 71 ACTEMRA TM 71 Cloretazine ® 71 refractory CTCL 70 rALLy clinical trial 70 axitinib 70 severe hypercholesterolemia 70 unresectable stage 70 Cloretazine 70 pegylated interferon alpha 70 refractory PTCL 70 CYT# potent vascular disrupting 70 sunitinib malate 70 histone deacetylase HDAC inhibitor 70 dose escalation clinical 70 Phase IIIb clinical 70 lymphoma CTCL 70 PEGINTRON TM 70 gemcitabine carboplatin 70 virus HCV protease inhibitor 70 Phase Ib study 70 assessing T DM1 70 FOLOTYN ® 70 primary hypercholesterolemia 70 refractory acute myeloid 70 Gemzar ® 70 sorafenib Nexavar ® 70 plus dexamethasone 70 naïve HCV 70 huN# DM1 70 bendamustine 70 imatinib Gleevec ® 70 forodesine 70 evaluating tivozanib 69 orally administered inhibitor 69 Vicinium TM 69 Pivotal Phase III 69 MAGE A3 ASCI 69 stage IIIB 69 lenalidomide Revlimid R 69 Pegasys ® 69 plus gemcitabine 69 TO AVOID PREGNANCY WHILE 69 receptor tyrosine kinase inhibitor 69 metastatic colorectal carcinoma 69 unresectable 69 plus prednisone 69 Phase Ib clinical 69 dasatinib Sprycel 69 ribavirin RBV 69 platinum refractory 69 CIMZIA TM 69 phase IIb trial 69 nab paclitaxel 69 Phase Ib II 69 nilotinib Tasigna ® 69 sorafenib tablets 69 melphalan prednisone 69 recurrent glioblastoma 69 VEGFR2 inhibitor 69 galiximab 69 liposomal formulation 69 symptomatic BPH 69 stage IIIb IV 69 Omacetaxine 69 PNP inhibitor 69 phase IIb study 69 arsenic trioxide injection 69 sunitinib Sutent ® 69 trastuzumab Herceptin R 69 tumors GIST 69 carboplatin paclitaxel 69 alfa 2a 69 Phase 2b clinical 69 gemcitabine cisplatin 69 BR.# 69 IV NSCLC 69 YONDELIS 69 LUX Lung 68 treatment naïve genotype 68 anthracycline taxane 68 evaluating carfilzomib 68 vinorelbine 68 ongoing Phase 1b 68 Cloretazine R VNP#M 68 pertuzumab 68 ZACTIMA 68 recurrent malignant glioma 68 advanced hepatocellular carcinoma 68 Kit CD# positive 68 docetaxel chemotherapy 68 dose escalation phase 68 TORISEL 68 chlorambucil 68 mTOR inhibitor 68 diabetic neuropathic pain 68 phase IIa clinical 68 BRIM2 68 antibody MAb 68 TELCYTA 68 ara C 68 Quinamed 68 dextromethorphan quinidine 68 HGS# 68 PI3K/Akt pathway inhibitor 68 prostate cancer HRPC 68 HCV SPRINT 68 Proxinium TM 68 telaprevir dosed 68 TELINTRA 68 novel histone deacetylase 68 AVONEX ® 68 dacarbazine DTIC 68 pan HDAC inhibitor 68 evaluating Xcytrin 68 IMGN# 68 bevacizumab Avastin R 68 CIMZIA ™ 68 COU AA 68 dacarbazine 68 registrational trial 68 B CLL 68 SPRYCEL ® 68 lymphoid malignancies 68 Phase Ib 68 CD3 monoclonal antibody 68 dependent kinase inhibitor 68 adult chronic ITP 68 XL# XL# XL# 68 novel VDA molecule 68 cilengitide 68 PegIFN 68 AEGR 68 oral nucleoside analogue 68 familial amyloidotic polyneuropathy FAP 68 KRAS mutations occur 68 Perifosine KRX 68 Annamycin 68 modified glutathione analog 68 myelodysplastic syndrome MDS 68 Hsp# Inhibitor 68 LymphoStat B belimumab 68 Brentuximab Vedotin SGN 68 leukemia APL 68 HGS ETR2 68 biliary tract cancer 68 oral prodrug 68 bortezomib Velcade R 68 relapsed myeloma 68 HCD# [002] 68 standard chemotherapy regimen 68 Pharmacokinetics PK 68 relapsed refractory 68 FEMALES SHOULD BE ADVISED 67 Fludara 67 advanced metastatic renal 67 placebo controlled Phase 67 mapatumumab 67 opioid induced constipation OIC 67 advanced carcinoid 67 REVIVE Diabetes 67 alpha folate receptor 67 cetuximab Erbitux R 67 Pivotal Phase 67 5 fluorouracil leucovorin 67 dose cohorts 67 Aflibercept 67 Phase 1b clinical 67 essential thrombocythemia ET 67 neratinib 67 relapsing remitting MS RRMS 67 evaluating REVLIMID 67 Meets Primary Endpoint 67 XL# anticancer compounds 67 FOLFOX6 67 mCRC patients 67 multicenter Phase III 67 everolimus tablets 67 metastatic malignant melanoma 67 metastatic malignant 67 metastatic renal cell 67 Alocrest 67 achieved ACR# 67 mertansine 67 Phase 1b 67 Xanafide 67 Traficet EN 67 Peginterferon alfa 2b 67 elotuzumab 67 FOLFOX6 chemotherapy regimen 67 relapsed leukemia 67 multicenter Phase 67 placebo controlled Phase III 67 IMiDs 67 remission induction 67 metaglidasen 67 refractory indolent non 67 Peg IFN 67 metastatic castration resistant 67 refractory myeloma 67 catheter occlusion 67 ® lenalidomide 67 cancer neuroendocrine tumor 67 Folfox 67 Xeloda ® 67 ganetespib 67 non metastatic osteosarcoma 67 low dose cytarabine 67 FOLFIRI 67 AVASTIN 67 INCB# [001] 67 blinded randomized placebo controlled 67 TMC# C# 67 HuMax EGFr 67 PEGylated interferon beta 1a 67 PEG PAL 67 adalimumab Humira 67 cetuximab Erbitux ® 67 Tanespimycin 67 R sorafenib tablets 67 q#h 67 ZOLINZA 67 acyclovir Lauriad R 67 Phase 2a trial 67 OncoVEX GM CSF 67 imatinib resistant 67 DOXIL 67 metastatic castrate resistant 67 PDX pralatrexate 67 romidepsin 67 docetaxel Taxotere ® 67 certolizumab 67 huC# DM4 67 opioid induced bowel dysfunction 67 follicular lymphoma FL 67 5 FU leucovorin 67 estramustine 67 Bezielle 67 crizotinib PF # 67 Aplidin R 67 Phase 2a clinical 67 phase Ib 67 #mg/m# [001] 67 metastatic HRPC 67 8mg/kg 67 painful diabetic neuropathy 67 refractory peripheral T 67 interferon alfa 2a 67 Zenvia TM 67 mCRC 67 non splenectomized 67 q8h 67 interferon gamma 1b 67 IV metastatic melanoma 67 SCH # 67 4mg/kg 67 AAG geldanamycin analog 67 herpetic keratitis 67 monoclonal antibody IgG1 Mab 67 Phase IIa trials 67 Navelbine ® 67 EGFR expressing mCRC 67 receiving highly emetogenic 67 plus dacarbazine 67 Initiate Phase 67 cisplatin gemcitabine 67 elacytarabine 67 systemic ALCL 67 castration resistant prostate cancer 66 evaluable subjects 66 visilizumab 66 oxymorphone ER 66 relapsed SCLC 66 unique alkylating agent 66 Acute Myeloid Leukemia AML 66 IMA# 66 Taxotere ® 66 doxorubicin HCl liposome injection 66 oblimersen 66 Diffuse Large B 66 unresectable Stage III 66 acute coronary syndromes ACS 66 IL# PE#QQR 66 gemcitabine Gemzar ® 66 trabectedin 66 randomized Phase IIb 66 sorafenib Nexavar 66 docetaxel Taxotere 66 subcutaneously administered 66 autoantibody positive 66 registrational Phase 66 paclitaxel Taxol ® 66 Golimumab 66 mGluR5 negative 66 Albuferon TM 66 budesonide foam 66 TASKi2 66 vandetanib 66 atypical Hemolytic Uremic Syndrome 66 recurrent metastatic ovarian cancer 66 dose escalation Phase 66 investigational immunotherapy 66 MabCampath 66 baminercept 66 Combination REOLYSIN R 66 IMiDs R 66 dose escalation trial 66 refractory DLBCL 66 Doxil ® 66 rALLy 66 Sapacitabine 66 pomalidomide 66 relapsed CLL 66 PXD# 66 HCV RESPOND 2 66 temsirolimus Torisel ® 66 GW# [003] 66 #mg QD [002] 66 unresectable malignant mesothelioma UMM 66 Ophena TM 66 Ceflatonin R 66 amrubicin 66 Zenvia ™ 66 plus prednisone prednisolone 66 developing Bicifadine serotonin 66 Jevtana 66 Randomized Phase II 66 recurrent GBM 66 INSPIRE Trial Phase III 66 bevacizumab Avastin ® 66 Romidepsin 66 phase IIb 66 CHOP chemotherapy 66 Phase IIa trial 66 regorafenib 66 paclitaxel Taxol R 66 BAY #-# 66 refractory follicular lymphoma 66 PSMA ADC 66 ALN HPN 66 Myelodysplastic Syndrome MDS 66 metastatic RCC 66 intravesical infusion therapy 66 xanthine oxidase inhibitor 66 randomized Phase III 66 Panzem R NCD 66 Phase 2b Clinical Trial 66 stage IIIb 66 Allovectin 7 ® 66 hormone refractory metastatic prostate 66 CR# vcMMAE 66 CLL SLL 66 mitoxantrone plus 66 splenectomized 66 chronic ITP patients 66 relapsing remitting multiple sclerosis 66 follicular NHL 66 liposomal doxorubicin 66 Epothilone D 66 generation purine nucleoside 66 Copegus ribavirin 66 idarubicin 66 CCX# B 66 previously untreated follicular 66 infliximab monotherapy 66 Fludarabine 66 EOquin TM 66 placebo dexamethasone 66 Ibritumomab Tiuxetan 66 AEG# 66 erlotinib Tarceva R 66 ceftazidime 66 Diabetic Macular Edema 66 myelodysplastic myeloproliferative diseases 66 receiving INTRON 66 vinca alkaloid 66 IMiDs ® compound 66 registrational 66 chronic lymphocytic leukemia CLL 66 adecatumumab 66 Epratuzumab 66 pegylated liposomal doxorubicin 66 IIIa inhibitor 66 ritonavir boosted 66 temsirolimus 66 ThermoDox R 66 evaluating picoplatin 66 oral vancomycin 66 diarrhea predominant irritable 66 refractory gout 66 Dacogen injection 66 NATRECOR R 66 docetaxel prednisone 66 R lenalidomide 66 Ozarelix 66 intravenous RSD# 66 zanolimumab 66 RANK Ligand inhibitor 66 Phase 1b trial 66 decitabine 66 stable angina pectoris 66 serologically active systemic lupus 66 Triapine 66 relapsed Hodgkin lymphoma 66 Randomized Phase 66 teriflunomide 66 hyperphenylalaninemia HPA due 66 FOLFOX regimen 66 lupus nephritis 65 rituximab refractory 65 abiraterone acetate 65 dose cohort 65 dirucotide 65 Virulizin ® 65 chemotherapy cisplatin 65 mg QD 65 aflibercept VEGF Trap 65 EDEMA3 65 phase III isavuconazole 65 alpha 2b 65 Panzem R 65 XL# XL# 65 doxorubicin cyclophosphamide 65 pegylated interferon alfa 2a 65 CD4 monoclonal antibody 65 null responder HCV 65 Ceflatonin 65 castrate resistant prostate cancer 65 Peginterferon 65 evaluating T DM1 65 INVANZ 65 dose cytarabine 65 Relapsed Refractory 65 TYKERB 65 XELOX 65 EFAPROXYN 65 CoFactor 65 superficial bladder cancer 65 miconazole Lauriad ® 65 refractory HL 65 Voreloxin 65 metastatic colorectal 65 Daclizumab 65 ofatumumab HuMax CD# 65 lintuzumab 65 mg q#h 65 metastatic CRPC 65 Aryplase 65 IMC A# 65 Vidaza ® 65 resistant ovarian cancer 65 LymphoStat B TM 65 neoadjuvant 65 heavily pretreated patients 65 ponatinib 65 Irinotecan 65 COMFORT II 65 Phase III randomized controlled 65 azacitidine 65 INC# 65 ELACYT 65 induced macular edema 65 CTAP# Capsules 65 AKT inhibitor 65 PREZISTA r 65 non nucleoside inhibitor 65 PKC# 65 anticancer compound 65 unstable angina UA 65 PROVENGE sipuleucel T 65 AIR CF1 65 Plicera 65 esophageal candidiasis 65 Phase IIb clinical 65 anti leukemic 65 oropharyngeal candidiasis OPC 65 cyclophosphamide methotrexate 65 HuMax CD4 65 gastrointestinal stromal tumor GIST 65 glioblastoma multiforme GBM 65 Phenoptin 65 Phase 1a clinical 65 oral rivaroxaban 65 Phase 2b study 65 pancreatic NET 65 multiple myeloma MM 65 FOLFOX4 65 Zorbtive TM 65 pseudobulbar affect PBA 65 influenza BCX# purine nucleoside 65 Complicated Skin 65 PEG SN# 65 JAK inhibitor 65 Clolar ® 65 CML CP 65 lumiliximab 65 investigational monoclonal antibody 65 randomized controlled Phase 65 pivotal Phase III 65 occlusion PAO 65 IIb clinical trial 65 prokinetic agent 65 biologic therapy 65 Archexin 65 oral picoplatin 65 irinotecan containing 65 fallopian tube carcinoma 65 immunotherapeutic agent 65 capecitabine Xeloda 65 BCG refractory carcinoma 65 ofatumumab 65 R roscovitine CDK cyclin 65 pegfilgrastim 65 Elotuzumab 65 Bortezomib 65 DEB# 65 CA4P 65 Azedra 65 MEK Inhibitor 65 Ceplene/IL-2 65 Ph + ALL 65 PEGylated Fab fragment 65 gemcitabine chemotherapy 65 Genasense ® 65 CALGB # [002] 65 targeted radiotherapeutic 65 CLARITY study 65 Tamibarotene 65 refractory APL 65 Phase IIb Trial 65 hematological malignancies 65 Degarelix 65 omacetaxine mepesuccinate 65 Paraplatin ® 65 dosing cohorts 65 Enzastaurin 65 enzastaurin 65 PRTX 65 active comparator 65 ribavirin Copegus ® 65 generation Hsp# inhibitor 65 Phase IIb Clinical Trial 65 plus COPEGUS 65 OMP #R# 65 lenalidomide Revlimid ® 65 LHRH receptor positive 65 non metastatic resectable 65 leukemia ALL 65 brand ciclesonide HFA 65 Pegasys plus Copegus 65 Elagolix 65 ixabepilone 65 Fibrillex TM 65 TLK# 65 Phase #/#a trial 65 biologic DMARD 65 IMiDs ® 65 MT# MEDI 65 IgG1 monoclonal antibody 65 Perifosine 65 MEND CABG II 65 Aplidin 65 Dementia Related Psychosis 65 Pivotal Trial 65 Newly Diagnosed Multiple Myeloma 65 Panzem NCD 65 romiplostim 65 radiation sensitizer 65 oral allopurinol 65 IMPACT IMmunotherapy 65 MGd 65 SUTENT 65 eribulin mesylate 65 HBeAg negative 65 weekly subcutaneous injections 65 plus DOXIL 65 Gleevec resistant 65 BENLYSTA ® 65 luteinizing hormone releasing 65 urocortin 2 65 ZYBRESTAT fosbretabulin 65 Oral NKTR 65 Hormone Refractory Prostate Cancer 65 vinorelbine tartrate 65 CIMZIA TM certolizumab pegol 65 investigational antiplatelet agent 65 perifosine 65 gastrointestinal stromal tumors GIST 65 TKB# 65 hA# 65 CANCIDAS 65 OvaRex ® MAb 64 novel topoisomerase 64 follicular non 64 fluoropyrimidine 64 HGS ETR1 64 unresectable locally advanced 64 subcutaneous formulation 64 Severe Sepsis 64 #mg/m# [002] 64 APTIVUS r 64 refractory colorectal cancer 64 mixed dyslipidemia 64 arthritis PsA 64 myelofibrosis MF 64 ISTODAX ® 64 Follicular Lymphoma 64 partial remissions 64 Phase Ib clinical trials 64 dose dose escalation 64 phase Ib clinical 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 Cimzia TM 64 trastuzumab DM1 T DM1 64 tocilizumab 64 μg dose 64 delivers fluocinolone acetonide FA 64 glufosfamide 64 interferon beta 1a infertility 64 aplastic anemia AA 64 KRAS wild 64 palifosfamide 64 Fludara ® 64 Phase Ib IIa 64 untreated multiple myeloma 64 multi kinase inhibitor 64 lexidronam injection 64 RCW breast cancer 64 novel emulsion formulation 64 celgosivir 64 oral chemotherapeutic agent 64 evaluating mipomersen 64 tamibarotene 64 hepatitis C HCV 64 intravenous belinostat 64 formerly LymphoStat B 64 Diabetic Macular Edema DME 64 Lenalidomide 64 APEX PD 64 cyclophosphamide chemotherapy 64 thymalfasin 64 papillary renal cell carcinoma 64 mGluR5 NAM 64 paclitaxel carboplatin 64 investigational humanized monoclonal antibody 64 ELOXATIN 64 Blinatumomab 64 Cariprazine 64 sunitinib 64 Neulasta R 64 oral FTY# 64 humanized interleukin 6 64 mg administered orally 64 investigational pan BCR 64 relapsed refractory AML 64 inhibitor RG# 64 MEK inhibitor 64 Myelofibrosis 64 MKC# MT 64 myelofibrosis 64 post herpetic neuralgia PHN 64 placebo controlled clinical 64 colorectal liver metastases 64 #mg BID [001] 64 PRECiSE 64 sunitinib Sutent 64 medullary thyroid cancer 64 BARACLUDE ® 64 Ixempra 64 Phase #b/#a 64 IIa trial 64 SUPPRELIN R LA 64 mg BID 64 pegylated interferon alfa 64 EOquin 64 EURIDIS 64 refractory systemic anaplastic 64 selective modulator 64 EOquin TM phase 64 mcg albinterferon alfa 2b 64 indolent NHL 64 dirucotide MBP# 64 reslizumab 64 urate lowering 64 Hodgkin lymphoma HL 64 hematologic malignancies 64 IMC #B 64 Flu Cy 64 thalidomide Thalomid 64 beta 1a 64 gefitinib Iressa 64 interferon alfa 2b 64 SAR# [004] 64 depsipeptide 64 Phase 2b trial 64 Soft Tissue Sarcoma 64 LUMINATE 64 hormone refractory prostate cancer 64 non resectable 64 metastatic pancreatic 64 pegylated interferon peg IFN 64 perifosine KRX 64 EGFR HER2 64 pan histone deacetylase 64 anthracyclines taxanes 64 humanized anti 64 adriamycin 64 AQ4N 64 TTF Therapy 64 Acute Myelogenous Leukemia AML 64 DAPT 64 multicentre randomized 64 Vascular Disrupting Agent 64 unresectable recurrent 64 Chronic Lymphocytic Leukemia CLL 64 Campath alemtuzumab 64 Phase III Pivotal 64 demonstrated antitumor activity 64 Intervention Effectiveness 64 KRN# 64 BCX# 64 TAXOTERE R 64 peginterferon alfa 2a 64 temsirolimus Torisel 64 indolent follicular non 64 initiate Phase 1b 64 VNP#M 64 receiving prophylactic anticoagulation 64 Pertuzumab 64 candesartan cilexetil 64 protease inhibitor PI 64 NYHA Class II 64 Advaxis Phase 64 develop HBV reactivation 64 ILUVIEN ® 64 peripheral sensory neuropathy 64 de novo kidney transplant 64 CD# monoclonal antibody 64 pediatric acute lymphoblastic 64 Raptiva ® 64 TG MV 64 IAP inhibitor 64 overactive bladder syndrome 64 apoptosis inducer 64 carfilzomib 64 Evoltra ® 64 eltrombopag 64 sodium glucose cotransporter 64 phase IIa 64 Hepatocellular Carcinoma HCC 64 achieved CCyR 64 lesinurad 64 ularitide 64 ® bortezomib 64 monotherapy 64 AA amyloidosis 64 CTA# Injection 64 infusional 5-FU/LV 64 Rebif ® 64 tumor lysis syndrome 64 sodium Injection 64 alkylating agent 64 relapsed ovarian cancer 64 octreotide implant 64 ThermoDox ® 64 bortezomib Velcade 64 eosinophilic asthma 64 refractory acute promyelocytic 64 oral proteasome inhibitor 64 evaluating Actimmune 64 Initiated Phase 64 TheraCIM 64 PegIntron 64 Genasense oblimersen sodium Injection 64 investigational protease inhibitor 64 IV melanoma 64 echinocandin 64 Nexavar sorafenib 64 randomized Phase 64 HBeAg negative patients 64 AIR CF2 64 individualized cellular immunotherapy 64 Advanced Renal Cell 64 peginterferon alfa 2b 64 Phase 1b clinical trials 64 hepatocellular carcinoma HCC 64 carcinoma mCRC 64 nucleoside analog 64 Peginterferon Alfa 2a 64 Tiuxetan 64 dose dexamethasone 64 INCB# [003] 64 budesonide MMX ® 64 Lenocta 64 acyclovir Lauriad ® 64 Seliciclib 64 Pegylated Liposomal Doxorubicin 64 Tyrima 64 metastatic bladder 64 trastuzumab Herceptin ® 63 myelodysplastic syndromes MDS 63 systemic RNAi therapeutic 63 Glufosfamide 63 Telik logo TELINTRA 63 Metastatic Melanoma 63 cytarabine daunorubicin 63 R Saizen R 63 leading oral taxane 63 Phase IIb trials 63 CHAMPION PCI 63 migraine headaches AZ 63 PROSTVAC ® 63 evaluating satraplatin 63 investigational oral inhibitor 63 RoACTEMRA 63 Granted Orphan Drug 63 transthyretin mediated amyloidosis ATTR 63 Interferon beta 1a 63 methylnaltrexone bromide 63 unfractionated heparin UFH 63 Myocardial Infarction Study 63 paroxysmal nocturnal hemoglobinuria PNH 63 FluCAM 63 Mitoxantrone 63 pegylated interferons 63 hydroxymethyl coenzyme 63 CONQUER OB 63 Castration Resistant Prostate Cancer 63 HGS ETR1 mapatumumab 63 epirubicin cyclophosphamide 63 mg TID 63 relapsed acute myelogenous 63 dosing cohort 63 Clevudine 63 Cell Lymphoma 63 obatoclax 63 Camptosar ® 63 BENLYSTA belimumab 63 somatostatin analog 63 adjuvant GIST 63 Nexavar ® 63 Taxotere R 63 monoclonal antibody conjugated 63 PHX# 63 hypoxia activated prodrug 63 potent triglyceride lowering 63 Cimzia ® certolizumab pegol 63 neurogenic orthostatic hypotension 63 pegylated interferon alpha 2a 63 volociximab 63 XL# SAR# 63 entinostat 63 dacetuzumab 63 cell lymphoma PTCL 63 Tipranavir 63 comparator arm 63 Oral Fingolimod 63 Metastatic Colorectal Cancer 63 fistulizing Crohn disease 63 Carfilzomib 63 R# #mg BID 63 Omacetaxine mepesuccinate 63 COPEGUS 63 HCV protease inhibitor 63 triciribine phosphate monohydrate 63 unresectable liver cancer 63 double blinded placebo 63 SUCCEED trial 63 abacavir lamivudine 63 LEXIVA r 63 APTIVUS 63 invasive candidiasis 63 2 methoxyestradiol 63 anti TNF alpha 63 toenail onychomycosis 63 REVLIMID ® 63 smoldering multiple myeloma 63 drug pipeline TAFA# 63 Phase 2b clinical trials 63 metformin sulfonylurea 63 mcg BID 63 severe gastroparesis 63 ARIXTRA 63 FOLOTYN 63 Vicriviroc 63 Multiple Myeloma MM 63 TM pralatrexate injection 63 HCV NS5B polymerase 63 Zenvia Phase III 63 vaccines oncolytic virus 63 BRIM3 63 hormone LHRH antagonist 63 LEUKINE 63 Zevalin R Ibritumomab 63 Bendamustine 63 panitumumab Vectibix 63 calcineurin inhibitor 63 gemcitabine Gemzar 63 TNF antagonists 63 uric acid lowering 63 pediatric Crohn disease 63 taxane resistant 63 Aptivus ® 63 angiotensin receptor blocker ARB 63 ADP receptor antagonist 63 Phase 2b Study 63 rilonacept 63 Phase IIa clinical 63 Chronic Hepatitis C 63 pralatrexate injection folate analogue 63 PEG interferon 63 cancer mCRC 63 recurrent metastatic 63 FOLFOX 63 talactoferrin 63 dacetuzumab SGN 63 BUPHENYL 63 peginterferon alfa 2a Pegasys 63 fosbretabulin 63 cell carcinoma RCC 63 plus methotrexate 63 refractory systemic ALCL 63 sapacitabine CYC# 63 ENESTnd 63 APPRAISE 63 eculizumab 63 Initiates Phase II 63 chronic idiopathic thrombocytopenic purpura 63 Chronic Lymphocytic Leukemia 63 oral deforolimus 63 TEMODAL 63 MyVax R 63 Neulasta ® 63 paclitaxel cisplatin 63 Xcellerated T Cells 63 peritumoral brain edema 63 Alkeran 63 patients undergoing percutaneous 63 Triapine R 63 rheumatoid arthritis RA psoriatic 63 vascular disrupting agent 63 Ovitrelle R Serostim 63 investigational compound 63 EQUIP OB 63 Xcytrin 63 Imprime PGG 63 myocardial infarction ventricular fibrillation 63 CD# antibody [001] 63 R rilonacept Injection 63 Hodgkin lymphoma NHL 63 Free Survival PFS 63 small lymphocytic lymphoma 63 desvenlafaxine succinate 63 cell chronic lymphocytic 63 immunomodulatory therapy 63 ribavirin therapy 63 pediatric malignancies 63 hypereosinophilic syndrome 63 ARCOXIA